AVXL · Transaction Dec 12, 2022 · Filed Jan 20, 2023 · $1,001 to $15,000
XNAS · AVXL
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Anavex Life Sciences
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$3.24
Veridion Score
BETALOW CONF · 5/6 factorsFri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET · AVXL
MethodologySentiment absence reason unknown
AVXL
Anavex Life Sciences
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
NEUTRAL
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is AVXL moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Anavex Life Sciences
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
2006
Employees
34
Country
US
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$3.24
Last session
Day high
$3.24
Last session
Day low
$3.24
Last session
Previous close
$3.24
52W high
$10.26
-68.42% from high
52W low
$2.34
11% of range
Market cap
$300.3M
EPS
$-0.4900
Beta
2.14
Shares out
92.7M
Avg volume
925.6K
VWAP
$3.24
Last session
Price history computed in-house
1W
+0.93%
1M
+35.00%
3M
+19.56%
1Y
-66.00%
YTD
-8.99%
SMA 50 $2.77 · above
SMA 200 $3.65 · below
52W position 11%
AVXL overview
Related filings and maps
Public disclosures
Congress activity in AVXL
Official filing ↗
AVXL · Transaction Oct 12, 2022 · Filed Nov 16, 2022 · $1,001 to $15,000
Federal contracts
AVXL contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AVXL in this window.
Lobbying spend
AVXL lobbying filings, year to date.
Registered lobbying filings matched to Anavex Life Sciences.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AVXL in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for AVXL.
Options
Sovereign unlock shows live options positioning for AVXL.